FDA Basics Webinar: A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS)
In 2007, a new law that gave FDA many new authorities and responsibilities to enhance drug safety was enacted. It's called the Food and Drug Administration Amendments Act- sometimes called "FDAAA"- and one of its provisions gave FDA the authority to require a Risk Evaluation and Mitigation Strategy-(REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.
A REMs may be required by the FDA as part of the approval of a new product, or for an approved product when new safety information arises. Essentially, a REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use.
Since medicines are very different from each other, each REMS for each medicine is also different.
This presentation discussed REMS and how they are used to help ensure that the benefits of certain medicines continue to outweigh their risks.
A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS)
Adobe Connect link
FDA Basics Webinar: A Brief Overview of REMS(PDF - 1.2MB)
Download Presentation Slides
- FDA Basics Metrics: February 2014
- What is the Reportable Food Registry?
- How do I report a complaint about food bought in a supermarket?
- What Rules Apply to Persons that Want to Start a Food Business?
- Is "over the counter (OTC)" medication safe for my child?
- FDA Basics Metrics: January 2014
- What does FDA inspect?
- When and why was FDA formed?
- What is a biological product?
- FDA Basics Metrics: December 2013
- FDA Basics Metrics: November 2013
- Webinar: 20 Years Later – Returning to FDA to Regulate Tobacco
- What doesn’t FDA regulate? How do I contact the agencies that do?
- FDA Basics Metrics: October 2013
- FDA Basics Metrics: August 2013
- FDA Basics Metrics: September 2013
- FDA Webinar on Tattoos and Permanent Makeup
- FDA Basics Webinar August 19, 2013: Biological Products, Part 2: Biosimilar Biological Products
- FDA Basics Metrics : June 2013
- FDA Basics Metrics: July 2013
- July: CBER's Direct Recall Classification Program
- Webinar on FDA’s Safety Monitoring of Approved Vaccines
- What is the FDA doing to protect children from tobacco?
- Can you explain the approval process for animal drugs?
- Does FDA have any other food safety materials?
How helpful was this information?